According to a recent announcement, Soligenix Inc. -- a late-stage biopharmaceutical company that creates products for inflammation, biodefense and oncology, as well as other similar unmet medical needs -- has partnered with the University of Hawaii at Manoa and Hawaii Biotech to create an Ebola vaccine that is heat stable.
"There is a great need for a thermostable Ebola vaccine, particularly in
areas of the world where Filoviruses are endemic and the power supply
uncertain," Dr. Axel Lehrer, assistant professor, department of tropical medicine, medical microbiology and pharmacology at the JABSOM, said.
"We are delighted to pursue this feasibility work with Soligenix and
look forward to a long and productive collaboration."
Previous evidence suggests that Soligenix’s thermostabilization technology, ThermoVax, may make it possible to create heat-stable Ebola vaccines.
"Coupling Soligenix's thermostabilization technology with Hawaii Biotech's robust manufacturing processes has the potential to yield a much needed vaccine to add to the world's arsenal against infectious disease and we look forward to working with both Soligenix and the JABSOM, UH Manoa," D. Elliot Parks, Ph.D., president and CEO of Hawaii Biotech, said.
scientists hope to create this product and then distribute it around the
world; creating a heat stable vaccine would make it more accessible for
countries with limited resources.
"We believe that creating a vaccine with enhanced stability at elevated temperatures, which can obviate the costs and logistical burdens associated with cold chain storage and distribution, has the potential to provide a distinct advantage over other Ebola vaccines currently in development," Soligenix President and CEO Christopher J. Schaber, Ph.D., said. "We are continuing to develop ThermoVax using RiVax, our proprietary ricin vaccine, under a recent National Institute of Allergy and Infectious Diseases (NIAID) contract award of up to $24.7 million over six years. We intend to apply this same technology beyond biodefense to emerging infectious diseases and see this collaboration with UH Manoa and Hawaii Biotech to be an important next step in demonstrating the broad applicability of this technology.”